Dehui Zou
YOU?
Author Swipe
View article: Association between stress hyperglycemia ratio and all-cause mortality in patients with acute kidney injury: a retrospective analysis of the MIMIC-IV database using machine learning
Association between stress hyperglycemia ratio and all-cause mortality in patients with acute kidney injury: a retrospective analysis of the MIMIC-IV database using machine learning Open
View article: Effect of bone marrow mononuclear cells therapy on long-term survival of patients with liver cirrhosis: A 10-year retrospective cohort study using propensity score matching
Effect of bone marrow mononuclear cells therapy on long-term survival of patients with liver cirrhosis: A 10-year retrospective cohort study using propensity score matching Open
Background Bone marrow mononuclear cells (BMMNCs) therapy should be effective for the improvement of liver function and short-term outcome in patients with liver cirrhosis, but few studies have explored the long-term prognosis of cirrhotic…
View article: DC-VideoGen: Efficient Video Generation with Deep Compression Video Autoencoder
DC-VideoGen: Efficient Video Generation with Deep Compression Video Autoencoder Open
We introduce DC-VideoGen, a post-training acceleration framework for efficient video generation. DC-VideoGen can be applied to any pre-trained video diffusion model, improving efficiency by adapting it to a deep compression latent space wi…
View article: DC-Gen: Post-Training Diffusion Acceleration with Deeply Compressed Latent Space
DC-Gen: Post-Training Diffusion Acceleration with Deeply Compressed Latent Space Open
Existing text-to-image diffusion models excel at generating high-quality images, but face significant efficiency challenges when scaled to high resolutions, like 4K image generation. While previous research accelerates diffusion models in …
View article: Monoclonal gammopathy defines distinct clinical subsets in Chronic Lymphocytic Leukemia across therapeutic eras
Monoclonal gammopathy defines distinct clinical subsets in Chronic Lymphocytic Leukemia across therapeutic eras Open
Monoclonal gammopathy (MG) in chronic lymphocytic leukemia (CLL) portends heterogeneous outcomes, yet its molecular drivers and therapeutic implications remain undefined. In this retrospective analysis of 2,075 CLL patients (1999-2024), MG…
View article: Phase 2 Study of Relmacabtagene Autoleucel (CD19 CAR-T) for Relapsed/Refractory Mantle Cell Lymphoma in Chinese Adults
Phase 2 Study of Relmacabtagene Autoleucel (CD19 CAR-T) for Relapsed/Refractory Mantle Cell Lymphoma in Chinese Adults Open
Relma-cel, an anti-CD19 CAR-T therapy, is approved in China for R/R large B-cell lymphoma and follicular lymphoma. This phase 2, open-label, single-arm, multicenter study evaluated its efficacy and safety in Chinese patients with heavily p…
View article: 758 | CLINICAL OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HEPATOSPLENIC T‐CELL LYMPHOMA
758 | CLINICAL OUTCOMES OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH HEPATOSPLENIC T‐CELL LYMPHOMA Open
View article: 547 | A PROSPECTIVE MULTICENTER STUDY OF FCR ALTERNATING WITH IBRUTINIB IN TREATMENT‐NAIVE PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
547 | A PROSPECTIVE MULTICENTER STUDY OF FCR ALTERNATING WITH IBRUTINIB IN TREATMENT‐NAIVE PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA Open
View article: Comparison of total body irradiation (TBI) and Non-TBI conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with peripheral T cell lymphoma: a multicenter retrospective study in China
Comparison of total body irradiation (TBI) and Non-TBI conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with peripheral T cell lymphoma: a multicenter retrospective study in China Open
View article: 530 | PREDICTIVE VALUE OF ctDNA AND MRD DYNAMICS IN DIFFUSE LARGE B‐CELL LYMPHOMA: A PROSPECTIVE COHORT STUDY
530 | PREDICTIVE VALUE OF ctDNA AND MRD DYNAMICS IN DIFFUSE LARGE B‐CELL LYMPHOMA: A PROSPECTIVE COHORT STUDY Open
View article: Identification of a CAR‐Derived Clone by <scp>NGS</scp>‐Based <scp>MRD</scp> After Fully Human <scp>BCMA CAR</scp> T‐Cell Therapy in Multiple Myeloma
Identification of a CAR‐Derived Clone by <span>NGS</span>‐Based <span>MRD</span> After Fully Human <span>BCMA CAR</span> T‐Cell Therapy in Multiple Myeloma Open
View article: Supplemental Table 5 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Table 5 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Table 5. Factors associated with progression.
View article: Supplemental Table 6 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Table 6 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Table 6. The outcomes and disease status of patients who completed the treatment.
View article: Supplemental Figure 6 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Figure 6 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Figure 6. Swim lane plots of efficacy in patients treated with ZID.
View article: Supplemental Figure 4 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Figure 4 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Figure 4. Change of lymphocyte subsets before and after treatment.
View article: Supplementary Data 1 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplementary Data 1 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Inclusion and exclusion criteria, Exclusion criteria, Treatment termination criteria and exclusion criteria, Case exclusion criteria, General combined medication and supportive care
View article: Supplemental Figure 1 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Figure 1 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Figure 1. Schematic diagram of the research scheme.
View article: Supplemental Figure 2 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Figure 2 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Figure 2. Treatment flow chart.
View article: Supplemental Table 4 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Table 4 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Table 4. Factors associated with deep response rate after induction and at best response.
View article: Supplemental Figure 5 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Figure 5 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Figure 5. Survival outcomes in patients with or without deep remission.
View article: Supplemental Figure 3 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Figure 3 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Figure 3. Mutations and immunoglobulin heavy chain variable (IGHV) fragments of patients.
View article: Supplementary Table 1 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplementary Table 1 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplementary Table 1. Representativeness of Study Participants.
View article: Supplemental Table 2 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Table 2 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Table 2.The modified criteria from IWWM-6.
View article: Supplemental Table 3 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Supplemental Table 3 from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Supplemental Table 3.The results of chromosome karyotype in all the patients.
View article: Data from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study
Data from Zanubrutinib plus Ixazomib and Dexamethasone in Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Phase II Study Open
Purpose:Waldenström macroglobulinemia (WM) is a rare type of lymphoma, with no optimal treatment. Bruton’s tyrosine kinase inhibitors have shown promising outcomes, yet achieving deep remission (very good partial remission or complete remi…
View article: Indirect Comparisons of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with R/R MCL: An Extended Follow-up Analysis
Indirect Comparisons of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with R/R MCL: An Extended Follow-up Analysis Open
MAIC results demonstrated that zanubrutinib had significantly longer PFS compared with orelabrutinib in the treatment of patients with R/R MCL.
View article: The specific transcriptional profile and clonal selection of monoclonal gammopathy of undetermined significance-like behavior predict an exceptionally favorable prognosis in multiple myeloma
The specific transcriptional profile and clonal selection of monoclonal gammopathy of undetermined significance-like behavior predict an exceptionally favorable prognosis in multiple myeloma Open
Not available.
View article: Correction: Targeting stem cell niche can protect hematopoietic stem cells from chemotherapy and G-CSF treatment
Correction: Targeting stem cell niche can protect hematopoietic stem cells from chemotherapy and G-CSF treatment Open
View article: Head-Aware KV Cache Compression for Efficient Visual Autoregressive Modeling
Head-Aware KV Cache Compression for Efficient Visual Autoregressive Modeling Open
Visual Autoregressive (VAR) models have emerged as a powerful approach for multi-modal content creation, offering high efficiency and quality across diverse multimedia applications. However, they face significant memory bottlenecks due to …
View article: Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma
Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma Open